HBV and VZV seroprotection loss in MS patients under DMTArticle Published on 2023-02-012023-06-09 Journal: Multiple sclerosis and related disorders [Category] B형 간염, [키워드] anti-CD20 HBV Infection prevention multiple sclerosis seroprotection VZV. [DOI] 10.1016/j.msard.2022.104490 PMC 바로가기
Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemicArticle Published on 2023-02-012023-07-10 Journal: Journal of Neurology [Category] COVID19(2023년), [키워드] End of dosing interval symptoms (EDIs) Extended interval dosing (ExID) fatigue multiple sclerosis Natalizumab wearing-off symptoms (WoS). [DOI] 10.1007/s00415-022-11408-0 PMC 바로가기
Characteristics and management of multiple sclerosis patients during the Omicron era: is there a concern about the MS course in the face of the new variant of COVID-19?Observational Study Published on 2023-02-012023-07-10 Journal: Neurological Sciences [Category] COVID19(2023년), [키워드] COVID-19 multiple sclerosis omicron variant. [DOI] 10.1007/s10072-022-06447-4 PMC 바로가기 [Article Type] Observational Study
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tabletsReview Published on 2023-02-012023-05-31 Journal: Neurodegenerative Disease Management [Category] 두창, 수두, 홍역, [키워드] Chickenpox vaccine Cladribine tablets flu vaccine lay summary multiple sclerosis plain language summary. [DOI] 10.2217/nmt-2022-0026 PMC 바로가기 [Article Type] Review
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosisObservational Study Published on 2023-02-012023-07-11 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), [키워드] anti-SARS-CoV2 antibodies. B lymphocytes COVID-19 vaccination fingolimod multiple sclerosis [DOI] 10.1016/j.msard.2022.104494 PMC 바로가기 [Article Type] Observational Study
Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulatorsObservational Study Published on 2023-02-012023-07-11 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), [키워드] COVID-19 Disease modifying therapy multiple sclerosis SARS-CoV-2 vaccine. [DOI] 10.1016/j.msard.2022.104484 PMC 바로가기 [Article Type] Observational Study
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapyObservational Study Published on 2023-02-012023-07-11 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), [키워드] booster COVID-19 multiple sclerosis SARS-CoV-2 vaccine. [DOI] 10.1016/j.msard.2022.104486 PMC 바로가기 [Article Type] Observational Study
Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccineArticle Published on 2023-01-152023-07-11 Journal: Journal of the neurological sciences [Category] COVID19(2023년), [키워드] COVID-19 vaccines Disease-modifying therapies multiple sclerosis SARS-CoV-2. [DOI] 10.1016/j.jns.2022.120518 PMC 바로가기
Chickenpox and multiple sclerosis: A Mendelian randomization studyArticle Published on 2023-01-012023-05-31 Journal: Journal of medical virology [Category] 두창, 수두, 홍역, [키워드] Chickenpox mendelian randomization multiple sclerosis varicella-zoster virus infection. [DOI] 10.1002/jmv.28315 PMC 바로가기
Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosisArticle Published on 2022-12-312023-07-08 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), [키워드] adverse events BBIBP-CorV multiple sclerosis SARS-CoV-2, COVID-19 vaccines vaccine safety. [DOI] 10.1080/21645515.2022.2041945 PMC 바로가기